NTRA News and Press, Natera Inc. From 04/07/22

Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test PR Newswire AUSTIN, Texas , April 7, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the ...

Natera Adds to Organ Health Medical Affairs Leadership Team PR Newswire Sangeeta Bhorade , M.D., appointed as head of organ health medical affairs AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-f...

Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 Infection PR Newswire AUSTIN, Texas , April 1, 2022 /PRNewswire/ -- Natera , Inc. (NASDAQ: NTRA), a global leader ...

Natera Listed as One of World's Most Innovative Health Companies by Fast Company PR Newswire Company recognized for its ability to monitor therapy response with its Signatera™ MRD test AUSTIN, Texas , March 28, 2022 /PRNewswire/ -- Nate...

About a third of biotech companies will have one year of cash or less by the end of 2022, the Morgan Stanley analysts led by Matthew Harrison said this week based on a sample of 380 firms. While the number of companies requiring cash is similar to the levels seen before 2018 – 21, the ...

GNOM lacks efficient portfolio reshuffling and may not be able to gain from higher alpha-producing stocks in the near future. Despite being a ‘Genomic Revolution’ fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better ‘...

SOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers...

New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology PR Newswire Biopsy-matched study assesses pancreas rejection in the context of a simultaneous kidney-pancreas transplant AUSTIN, Texas ...

Natera Inc. (NASDAQ:NTRA) was named a new best idea at Piper Sandler as the firm sees a "modest, if any" impact on Natera's P&L from matters talked about in the Hindenburg short report. Piper Sandler spoke to a "key opinion leader" on Friday who said the short report likely "grossly embel...

Natera Announces Updated Signatera™ MRD Data from CIRCULATE-Japan Presented in Plenary Talk at the Society of Surgical Oncology Conference, and Activation of CIRCULATE-US Trial PR Newswire Updated analysis shows 75% detection of recurrence with a single blood dr...